Literature DB >> 17982069

IL-6 contributes to the expression of RAGs in human mature B cells.

Sophie Hillion1, Maryvonne Dueymes, Pierre Youinou, Christophe Jamin.   

Abstract

Mature B cells acquire the capacity to revise rearranged Ig V region genes in secondary lymphoid organs. In previous studies, we demonstrated that cross-linking the BCR and the CD40 induces the expression of the RAG1 and RAG2 enzymes and, thereby, secondary rearrangements. We examine herein the mechanism that underpins RAG1 and RAG2 expression in peripheral and tonsil B cells. Coordinated engagement of the BCR and CD40 promoted the synthesis of IL-6 and, thereby, up-regulation of its receptor on activated B lymphocytes. Furthermore, we provide evidence that IL-6 initiates the expression of RAGs in circulating B cells, and extends those in tonsil B cells. Thus, neutralization of IL-6 or blocking of its receptor inhibits RAG expression. Moreover, we demonstrate that IL-6 impedes BCR-mediated termination of RAG gene expression in both population of B cells. The recovered inhibition of RAG gene transcription by IL-6 receptor blockade supports the notion that once recombination is launched, its termination is also regulated by IL-6. Taken together, these studies provide new insight into the dual role of IL-6 in inducing and terminating expression of the recombinase machinery for secondary rearrangements in mature human B cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982069     DOI: 10.4049/jimmunol.179.10.6790

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Asbestos activates CH12.LX B-lymphocytes via macrophage signaling.

Authors:  Devon L Rasmussen; Jean C Pfau
Journal:  J Immunotoxicol       Date:  2011-12-01       Impact factor: 3.000

2.  Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice.

Authors:  Virginia A Carroll; Mark K Lafferty; Luigi Marchionni; Joseph L Bryant; Robert C Gallo; Alfredo Garzino-Demo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

3.  IL-6 contributes to an immune tolerance checkpoint in post germinal center B cells.

Authors:  Yi Yan; Ying-Hua Wang; Betty Diamond
Journal:  J Autoimmun       Date:  2011-12-07       Impact factor: 7.094

Review 4.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

5.  A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjögren's syndrome.

Authors:  Sarah Benchabane; Abdelhalim Boudjelida; Ryma Toumi; Houda Belguendouz; Pierre Youinou; Chafia Touil-Boukoffa
Journal:  Int J Immunopathol Pharmacol       Date:  2016-05-19       Impact factor: 3.219

Review 6.  Mechanisms controlling expression of the RAG locus during lymphocyte development.

Authors:  Tracy C Kuo; Mark S Schlissel
Journal:  Curr Opin Immunol       Date:  2009-04-07       Impact factor: 7.486

7.  Phosphorothioate-modified CpG oligodeoxynucleotides mimic autoantigens and reveal a potential role for Toll-like receptor 9 in receptor revision.

Authors:  Anne Doster; Saskia Ziegler; Sandra Foermer; Ralf Joachim Rieker; Klaus Heeg; Isabelle Bekeredjian-Ding
Journal:  Immunology       Date:  2013-06       Impact factor: 7.397

8.  Patterns of receptor revision in the immunoglobulin heavy chains of a teleost fish.

Authors:  Miles D Lange; Geoffrey C Waldbieser; Craig J Lobb
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

9.  CD40 interacts directly with RAG1 and RAG2 in autoaggressive T cells and Fas prevents CD40-induced RAG expression.

Authors:  Gisela M Vaitaitis; David H Wagner
Journal:  Cell Mol Immunol       Date:  2013-09-16       Impact factor: 11.530

10.  Lambda light chain revision in the human intestinal IgA response.

Authors:  Wen Su; John N Gordon; Francesca Barone; Laurent Boursier; Wayne Turnbull; Surangi Mendis; Deborah K Dunn-Walters; Jo Spencer
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.